STOCK TITAN
  1. Home
  2. News
  3. SKYE

Skye Bioscience Inc - SKYE STOCK NEWS

Welcome to our dedicated news page for Skye Bioscience (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Skye Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Skye Bioscience's position in the market.

News
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) has treated the first patient in its Phase 2 clinical trial evaluating SBI-100 Ophthalmic Emulsion’s ability to lower intraocular pressure, safety, and relevant biomarkers in patients with primary open-angle glaucoma or ocular hypertension. The Phase 2 study will compare two concentrations of SBI-100 OE vs. placebo, dosing twice a day for 14 days, with analysis of IOP data from 50% of patients enrolled to be performed in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit
Rhea-AI Summary
Skye Bioscience, Inc. (SKYE) to present its glaucoma program at two ophthalmology-focused conferences, showcasing SBI-100 Ophthalmic Emulsion, a first-in-class CB1 agonist. The company will introduce recent Phase 1 data and discuss details of its Phase 2a clinical study. Executives will be available for 1x1 meetings at the BTIG 3rd Annual Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
conferences
-
News
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
Rhea-AI Summary
Skye Bioscience reports successful results from Phase 1 trial of SBI-100 OE, an ophthalmic drug targeting glaucoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.24%
Tags
clinical trial
News
Skye Bioscience Reverse Stock Split to Be Effective on September 8th
Rhea-AI Summary
Skye Bioscience, Inc. announces 1-for-250 reverse stock split effective September 8th. Total issued and outstanding shares will be approximately 12,312,551. No fractional shares will be issued. Stockholders' ownership interest and voting power remain virtually unchanged.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27243.8%
Tags
none
-
News
Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Skye Bioscience to present company overview at H.C. Wainwright 25th 3rd Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
Rhea-AI Summary
Skye Bioscience expands resources and technologies with acquisition of Bird Rock Bio, raising $17M in new capital. Plans to advance Phase 2a glaucoma clinical trial with nimacimab and expects Phase 1 results for SBI-100 Ophthalmic Emulsion by end of Q3 2023. Skye's cash and cash equivalents expected to fund operations into 2024. Goal to uplist to a national stock exchange with proposed reverse stock split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.75%
Tags
acquisition clinical trial
News
Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
conferences
-
News
Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial
Rhea-AI Summary
Skye Bioscience announces completion of production of placebo and SBI-100 Ophthalmic Emulsion for its Phase 2a study of glaucoma and ocular hypertension. The study will primarily focus on the efficacy of a synthetic pro-drug in human subjects targeting the CB1 receptor to reduce intraocular pressure. Additional steps are required before the study can begin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
clinical trial
News
Skye Bioscience to Present at LD Micro Invitational XIII
Rhea-AI Summary
Skye Bioscience to present at 13th Annual LD Micro Invitational
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
conferences
Stock SKYE logo
Skye Bioscience Inc

OTC:SKYE

SKYE Rankings

#3030 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SKYE Stock Data

362.29M
11.67M
7.09%
57.67%
General Freight Trucking, Long-Distance, Truckload
Transportation and Warehousing
Link
US
San Diego

About SKYE

nemus bioscience is a publicly traded, life-science biotech company, developing regulatory-approved, cannabinoid-based therapies, for a spectrum of diseases, especially those of unmet medical need.